[
  {
    "ts": null,
    "headline": "Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC",
    "summary": "This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.",
    "url": "https://finnhub.io/api/news?id=ee5950b03d2aa7bef7cd7f6bd336147f0293d19d6bc4c1d539bf8dd974556ffa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733334000,
      "headline": "Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC",
      "id": 131769558,
      "image": "https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.",
      "url": "https://finnhub.io/api/news?id=ee5950b03d2aa7bef7cd7f6bd336147f0293d19d6bc4c1d539bf8dd974556ffa"
    }
  },
  {
    "ts": null,
    "headline": "PCRX Receives New Patent for Lead Pain Drug Exparel in the US",
    "summary": "The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.",
    "url": "https://finnhub.io/api/news?id=dd77309a9f86a3d08a7eb43a7b1839942ec397aa772c811790aa548fb1060183",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733332200,
      "headline": "PCRX Receives New Patent for Lead Pain Drug Exparel in the US",
      "id": 131769561,
      "image": "https://media.zenfs.com/en/zacks.com/6707b6de8d8e03441895b107371eec74",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.",
      "url": "https://finnhub.io/api/news?id=dd77309a9f86a3d08a7eb43a7b1839942ec397aa772c811790aa548fb1060183"
    }
  },
  {
    "ts": null,
    "headline": "ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD",
    "summary": "Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.",
    "url": "https://finnhub.io/api/news?id=e5e4ce25913a49fea33b2c0b7193b8f679208c78e9467a2c12c78972a4cf6704",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733331600,
      "headline": "ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD",
      "id": 131769562,
      "image": "https://media.zenfs.com/en/zacks.com/00e8f1a41a7bc7b2ecf8d421f3c6f574",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.",
      "url": "https://finnhub.io/api/news?id=e5e4ce25913a49fea33b2c0b7193b8f679208c78e9467a2c12c78972a4cf6704"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f1de8505133c5984105b8d6ef3a3786b664aa496736155d0782156e47a9b2921",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733330400,
      "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "id": 131777349,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f1de8505133c5984105b8d6ef3a3786b664aa496736155d0782156e47a9b2921"
    }
  },
  {
    "ts": null,
    "headline": "With 68% ownership, Pfizer Inc. (NYSE:PFE) boasts of strong institutional backing",
    "summary": "Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...",
    "url": "https://finnhub.io/api/news?id=02679827c17b7f335af1ebc065f4be75c3ca7cbe01ab0a56af6d96b7ba728246",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733317222,
      "headline": "With 68% ownership, Pfizer Inc. (NYSE:PFE) boasts of strong institutional backing",
      "id": 131766729,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8f018d189c2c443014c49845310ae091",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...",
      "url": "https://finnhub.io/api/news?id=02679827c17b7f335af1ebc065f4be75c3ca7cbe01ab0a56af6d96b7ba728246"
    }
  },
  {
    "ts": null,
    "headline": "Roivant Sciences: A Biotech Growth Play With Major Ambitions",
    "summary": "Roivant Sciences' diversified late-stage pipeline and robust financials promise significant growth potential. Read why I maintain my buy rating on ROIV stock.",
    "url": "https://finnhub.io/api/news?id=8551a75b4ebb977d420ef710d4ea926ee9217ede87b46cb8875f82f7e9775a1e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733301000,
      "headline": "Roivant Sciences: A Biotech Growth Play With Major Ambitions",
      "id": 131766090,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1150479205/image_1150479205.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Roivant Sciences' diversified late-stage pipeline and robust financials promise significant growth potential. Read why I maintain my buy rating on ROIV stock.",
      "url": "https://finnhub.io/api/news?id=8551a75b4ebb977d420ef710d4ea926ee9217ede87b46cb8875f82f7e9775a1e"
    }
  }
]